Dulbecco s modified eagle medium with low glucose

Experiments were performed using the HPV-negative HNSCC cell lines FaDu (hypopharyngeal, p53 mutated [59 (link)]) and UM-SCC-1 (oral cavity/mouth base, p53 non-mutated [60 (link)]). For both cell lines, a CRISPR-Cas9 FANCA ko was used in addition to the wild type (wt). The FA phenotype was confirmed by treatment with the DNA crosslinker Mitomycin C (Supplementary Figure S4). All cells were provided by the Fanconi cancer cell line repository (https://apps.ohsu.edu/research/fanconi-anemia/cell_line, e.g., accessed on 5 November 2019, [61 (link)]). Cells were cultured in Dulbecco’s Modified Eagle Medium with low glucose (Merck, Darmstadt, Germany) containing 1% non-essential amino acids (Merck, Germany), 15% fetal bovine serum (Merck, Darmstadt, Germany), and 1% penicillin/streptomycin (Merck, Germany). Cells were maintained in a humidified incubator at 5% CO₂ and 37 °C.

Experiments were performed using the HPV-negative HNSCC cell lines FaDu (hypopharyngeal, p53 mutated [59 (link)]) and UM-SCC-1 (oral cavity/mouth base, p53 non-mutated [60 (link)]). For both cell lines, a CRISPR-Cas9 FANCA ko was used in addition to the wild type (wt). The FA phenotype was confirmed by treatment with the DNA crosslinker Mitomycin C (Supplementary Figure S4). All cells were provided by the Fanconi cancer cell line repository (https://apps.ohsu.edu/research/fanconi-anemia/cell_line, e.g., accessed on 5 November 2019, [61 (link)]). Cells were cultured in Dulbecco’s Modified Eagle Medium with low glucose (Merck, Darmstadt, Germany) containing 1% non-essential amino acids (Merck, Germany), 15% fetal bovine serum (Merck, Darmstadt, Germany), and 1% penicillin/streptomycin (Merck, Germany). Cells were maintained in a humidified incubator at 5% CO₂ and 37 °C.